These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N; J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579 [TBL] [Abstract][Full Text] [Related]
6. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Miele L; Targher G Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399 [TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease and cardiovascular disease. Liu H; Lu HY World J Gastroenterol; 2014 Jul; 20(26):8407-15. PubMed ID: 25024598 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Lim S; Oh TJ; Koh KK Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987 [TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in patients with nonalcoholic fatty liver disease. Chatrath H; Vuppalanchi R; Chalasani N Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885 [TBL] [Abstract][Full Text] [Related]
13. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Martin A; Lang S; Goeser T; Demir M; Steffen HM; Kasper P Curr Atheroscler Rep; 2022 Jul; 24(7):533-546. PubMed ID: 35507279 [TBL] [Abstract][Full Text] [Related]
14. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634 [TBL] [Abstract][Full Text] [Related]
15. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Vural H; Armutcu F; Akyol O; Weiskirchen R Clin Chim Acta; 2021 Dec; 523():374-379. PubMed ID: 34678296 [TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. Milić S; Lulić D; Štimac D World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327 [TBL] [Abstract][Full Text] [Related]
20. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Taskinen MR; Borén J Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]